How to Help Your Patients Save Money on Insulin Glargine-Yfgn: A Provider's Guide to Savings Programs

With Semglee (insulin glargine-yfgn) discontinued as of December 31, 2025, your patients who were relying on Semglee's competitive pricing now need to find savings on alternative products. The good news: the insulin glargine cost landscape has improved significantly in recent years, with multiple $35/month programs and a new nonprofit pricing option from Civica Rx. This guide gives you everything you need to counsel patients on their cost-reduction options in 2026.

The 2026 Insulin Glargine Cost Landscape: What's Changed

Several major developments have reshaped insulin pricing in 2025–2026:

Sanofi's 78% list price reduction: Lantus list price was reduced substantially. After this reduction, Lantus costs approximately $80–$100 per vial or box of pens, and Sanofi's Valyou Savings Program caps it at $35/month regardless of insurance status.

IRA Medicare insulin cap: Effective 2024, the Inflation Reduction Act capped Medicare Part D insulin cost-sharing at $35/month for covered insulin products.

Civica Rx launch: The nonprofit Civica Rx launched unbranded insulin glargine-yfgn pens on January 1, 2026 at $45 for five pens — the lowest list price for any long-acting insulin in the US.

Semglee discontinuation: Biocon discontinued Semglee vials and pens December 31, 2025. Patients previously on Semglee may now face formulary coverage gaps or higher copays while plans update.

Program 1: Civica Rx Insulin Glargine-Yfgn — The Lowest Cash Price

For patients paying out of pocket, Civica Rx offers the lowest list price option. Civica is a nonprofit pharmaceutical company focused on ensuring essential medicine access and price stability. Their insulin glargine-yfgn:

Price: $45 for a box of 5 pens (recommended max consumer price: $55)

Manufactured by Biocon Biologics under its existing FDA marketing approval — same manufacturer as Semglee

Carries the same FDA interchangeable designation with Lantus as Semglee

Available at participating pharmacies nationwide; marketed as CalRx in California

For uninsured patients, or patients whose insurance doesn't cover insulin glargine-yfgn, this is the first recommendation. Prescribe 'insulin glargine-yfgn' generically, and advise patients to ask for the Civica Rx version specifically.

Program 2: Sanofi Valyou Savings Program (Lantus)

Because insulin glargine-yfgn is interchangeable with Lantus, patients who can't access affordable glargine-yfgn may be directed to Lantus with the Sanofi Valyou program. Key features:

Price cap: $35/month for all Sanofi insulins including Lantus

Eligibility: Both commercially insured and uninsured patients (income restrictions may apply for uninsured)

No new prescription needed: Lantus is interchangeable with insulin glargine-yfgn — pharmacists can substitute without prescriber intervention

Enrollment: sanofi.com/US/patients or 1-888-847-4877

Program 3: Eli Lilly $35/Month Program (Basaglar or Rezvoglar)

If a patient needs a new prescription and cannot access Lantus savings or Civica Rx pricing, Eli Lilly's $35/month program covers both Basaglar and Rezvoglar — both insulin glargine products at 100 units/mL:

Basaglar KwikPen: $35/month regardless of insurance status through Lilly's Insulin Value Program

Rezvoglar: also covered by Eli Lilly programs with strong availability

Note: Requires a new prescription — Basaglar and Rezvoglar are NOT interchangeable with insulin glargine-yfgn at the pharmacy level

38,224+ patients found their medications in stock

38K+

Find Insulin Glargine-Yfgn In Stock Today →

Program 4: Medicare Part D — IRA Insulin Cap

For Medicare patients, the IRA $35/month cap is critically important to communicate:

All covered insulin products under Part D are capped at $35/month cost-sharing as of 2024

Medicare Part D plans typically cover Lantus; coverage of insulin glargine-yfgn specifically varies by plan

Patients should check their plan's formulary for which insulin glargine product is covered

Extra Help / Low Income Subsidy (LIS): Qualifying Medicare patients with LIS pay even less — often $0–$10/month for covered insulins

Program 5: Patient Assistance Programs (PAPs) for Uninsured Patients

Sanofi Patient Connection: Free Lantus for qualifying uninsured patients. Apply at sanofi.com or 1-888-847-4877. Income and insurance requirements apply.

Lilly Cares Foundation: Free Basaglar for qualifying low-income uninsured patients. Apply at lillycares.com.

NeedyMeds.org: Comprehensive database of PAPs for insulin products. Useful for identifying lesser-known programs.

Skip the calls, skip the stress.

Find Insulin Glargine-Yfgn In Stock Today →

50K+

Medications
Found

99%

Success
Rate

6+

Hours saved
on average

Quick Decision Framework for Your Practice

Patient paying cash, no insurance → Civica Rx insulin glargine-yfgn ($45/5 pens)

Patient has commercial insurance, Lantus covered → Sanofi Valyou ($35/month)

Patient needs a new Rx for a different product → Basaglar with Eli Lilly program ($35/month)

Medicare patient → IRA $35/month cap on covered Part D insulin

Uninsured, low income → PAP (Sanofi Patient Connection or Lilly Cares)

For help finding pharmacies where patients can fill their insulin prescription, use medfinder's provider tools. For the full clinical shortage briefing, see: Insulin Glargine-Yfgn Shortage: What Providers Need to Know in 2026.